Adjuvant Treatment of Pulmonary Embolism With Drotrecogin Alfa (Activated): Phase II Exploratory Study

NCT00191724 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

47

Enrollment

INDUSTRY

Sponsor class

Conditions

Submassive Pulmonary Embolism

Interventions

DRUG: Drotrecogin Alfa (Activated)
DRUG: Enoxaparin
DRUG: Placebo
DRUG: Drotrecogin Alfa (Activated)
DRUG: Drotrecogin Alfa (Activated)
DRUG: Drotrecogin Alfa (Activated)

Sponsor

Eli Lilly and Company